Companies that want to accelerate their biomanufacturing operations and use their resources efficiently need access to technologies and solutions that can safely and efficiently complete their workflow from idea to injection.
William B. Jones, Senior Vice President of Pharmaceutical Development at Corvus Pharmaceuticals, discusses his company’s selection of CDMO for its CPI-006 antibody program, which is currently under development as an oncology drug and investigation as a therapeutic for immune disorders and infectious diseases.
Significant interest has been focused on the science of scale for spray drying. This paper identifies critical steps that can smooth the development pathway, eliminating scale-up headaches down the road.
Data and the digitization of assembly equipment work together to deliver competitive advantage to pharma partners in terms of product quality, continuous improvement, de-risking maintenance and change management, and the ability to deliver unique identities and traceability for every assembled device.
Some of the most important technologies available to formulators are those that enhance bioavailability, given the large percentage of low-solubility compounds in today’s pharmaceutical pipelines. Formulators have many choices in their toolkit when it comes to bioavailability enhancement, so the tough call becomes which one to use for a given compound. Lonza has developed a full complement of tools that accurately predict the performance of bioavailability-enhanced formulations.
Understand what goes into producing a vaccine, raw materials, technology, and a complex manufacturing process, and how and why CMOs and CDMOs are better positioned to bridge the gap between vaccine demand and supply, safely and at speed.